Cefotaxime Sodium Salt Powder, a broad-spectrum cephalosporin antibiotic, serves as a potent weapon against resistant bacterial strains. Its effectiveness extends to methicillin and Tetracycline resistant bacteria, making it a valuable choice in challenging infections.
This antibiotic’s mechanism of action involves binding to the 50S ribosomal subunit, a crucial step that halts bacterial growth. By targeting this key component, Cefotaxime Sodium Salt Powder effectively inhibits bacterial growth.
Moreover, this antibiotic’s low toxicity profile and minimal side effects enhance its appeal in clinical use. Healthcare professionals rely on Cefotaxime Sodium Salt Powder for its safety and effectiveness, especially in treating serious bacterial infections.
In research settings, Cefotaxime Sodium Salt Powder finds utility as a selective agent in microbial culture media. Its ability to inhibit bacterial growth, particularly in resistant strains, aids researchers in identifying and studying specific bacterial strains.
In summary, Cefotaxime Sodium Salt Powder’s broad-spectrum effectiveness, stability in formulations, and safety profile make it a valuable asset in medical treatment and research. Its role in combating resistant bacteria and treating diverse infections highlights its importance in healthcare.
| Cat. Number | AS-2027 |
| CAS Number | 64485-93-4 |
| Additional CAS | 63527-52-6 (acid) |
| MDL Number | MFCD00079073 |
| Pubchem | 310269492 |
| Molecular Weight | 477.40 gr/mol |
| Molecular Formula | C16H16N5NaO7S2 |
| Storage Temperature | +4°C |
| Form and Color | Powder to Crystalline Powder / White to light yellow |
| Solubility (10% in water) | Clear, Colorless to yellow solution |
| Absorbance | 430 nm: ≤ 0.2 |
| pH Value | 4.5 – 6.5 |
| Specific Optical Rotation | 58 – 64 ° |
| Total impurities (HPLC) | ≤ 3% |
| Assay (dried basis) | 916 – 964 µg/mg |
| Loss on Drying | ≤ 3% |
| 1H-NMR Spectrum | Corresponds to assigned structure |
